{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"57.4","upperLimit":"75.9","value":"67.6"}]}],"title":"Survival rate at 6 months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"35.7","upperLimit":"56.3","value":"46.3"}]}],"title":"Survival rate at 12 months"}],"denoms":[{"counts":[{"groupId":"OG000","value":"102"}],"units":"Participants"}],"description":"Percentage of participants alive at 6 and 12 months are reported. It was calculated using the Kaplan-Meier technique. CI for median PFS derived based on the Brookmeyer-Crowley method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants harboring tumors with specific HER2 activating mutations received T-DXd 5.4 mg/kg via IV infusion on Day 1 of each cycle (21 days), every 3 weeks until RECIST v1.1-defined PD, withdrawal of consent, or until any other of the discontinuation criteria was met.","id":"OG000","title":"T-DXd"}],"paramType":"NUMBER","populationDescription":"The FAS consisted of all participants who received at least 1 dose of study treatment.","reportingStatus":"POSTED","timeFrame":"At Months 6 and 12","title":"Percentage of Participants Alive at 6 and 12 Months","type":"SECONDARY","unitOfMeasure":"percentage of participants"}